• Restore CFTR ProteinCompleted with Results

  Study of ELX-02 in adults with cystic fibrosis who have at least one nonsense mutation. , protocol number Eloxx EL-012 (Kalydeco or Trikafta)

  This study evaluated the safety and tolerability of ELX-02, a drug intended to improve CFTR function. Multiple doses of ELX-02, both alone and with ivacaftor, were tested in adults with cystic fibrosis who have at least one G542X mutation. 

  • Age:

    18 Years and Older

  • Mutation(s):

    No Copies F508del

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    8

  • Length of Participation:

    9 weeks

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.